Delving into the Latest Updates on Mepolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Bosatria, Mepolizamab, Mepolizumab (Genetical Recombination)

+ [7]

Target

IL-5

Action

inhibitors

Mechanism

IL-5 inhibitors(Interleukin-5 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [5]

Active Indication

Pulmonary Disease, Chronic ObstructiveAsthmaChronic rhinosinusitis with nasal polyps+ [7]

Inactive Indication

Asthma, Nasal Polyps, and Aspirin IntoleranceDeglutition DisordersEosinophilic Esophagitis+ [5]

Originator Organization

GSK Plc

Active Organization

GSK PlcGlaxoSmithKline Trading Services Ltd.

GlaxoSmithKline (China) Investment Co., Ltd.

+ [4]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (04 Nov 2015),

Severe asthma

RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Sequence Code 42934L

Source: *****

Sequence Code 43483H

Source: *****

The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.

Start Date16 Oct 2024

Sponsor / Collaborator

Xijing Hospital

NCT06501807

/ Not yet recruitingNot ApplicableIIT

Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps

With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.
During the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.
New biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.
Herein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.Patient-reported outcomes will be addressed according to their initial clinical profile (allergy, asthma, NSAID, gastroesophageal reflux disease, obstructive apnea, otologic disorder, smoke habit).

Start Date02 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Mepolizumab

Login to view more data

100 Translational Medicine associated with Mepolizumab

Login to view more data

100 Patents (Medical) associated with Mepolizumab

Login to view more data

1,627

Literatures (Medical) associated with Mepolizumab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective

Article

Author: Romero, Jose ; Giovini, Vanina ; Espinoza, Manuel Antonio ; Balmaceda, Carlos ; Moraes dos Santos, Felipe ; Rodríguez Martínez, Consuelo

AIM:

Asthma is a heterogeneous respiratory condition often classified into distinct phenotypes. Severe asthma, characterized by uncontrolled symptoms despite optimal treatment, imposes a significant burden on healthcare systems, particularly in low- and middle-income countries. This study evaluates the cost-effectiveness of mepolizumab compared with other interleukin (IL)-5 pathway inhibitors, benralizumab and reslizumab, in treating severe asthma with an eosinophilic phenotype in Chile.

MATERIALS AND METHODS:

A Markov cohort model was developed to compare mepolizumab (100 mg subcutaneously every four weeks) with benralizumab (30 mg subcutaneously every four weeks for the first three doses, every eight weeks subsequently) and reslizumab (3 mg/kg intravenously every four weeks), both as add-on therapies to standard care. Data from the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) clinical trial and a network meta-analysis were used. Utility values were extracted using the EuroQoL 5-Dimension questionnaire (EQ-5D-5L) questionnaire. Probabilistic and one-way sensitivity analyses assessed model robustness.

RESULTS:

Mepolizumab demonstrated dominance with probability over 95% when compared with benralizumab and reslizumab. Cost savings ranged from 37,000 United States dollars (USD) to 104,000 USD, with an increase of 0.52 to 0.55 quality-adjusted life years. Mepolizumab was also associated with a lower incidence of exacerbations and asthma-related deaths. Sensitivity analyses confirmed the stability of the model outcomes across key parameters.

LIMITATIONS:

Limitations of the economic model are related to the lack of direct comparisons between mepolizumab and other biologics. Additionally, the absence of data on continuation criteria required estimating relative risks for the overall population.

CONCLUSIONS:

Mepolizumab offers greater efficacy and cost savings compared to benralizumab and reslizumab for eosinophilic asthma, providing essential insights for improving asthma management and informing healthcare policies in Chile.

01 Dec 2025·Current Cardiology Reports

Eosinophilic Myocarditis: A Concise Review

Review

Author: Kahwash, Rami ; Trovato, Vincenzo ; Asada, Ashlee M

Abstract:

Purpose of Review:

Eosinophilic myocarditis (EM) is a rare and heterogeneous form of inflammatory heart disease that can present with a wide range of severity. Current literature is limited to case reports or small case series that outline the evaluation process, disease course, and the nonstandardized treatments trialed. This review aims to concisely summarize the current literature on EM including an update on maintenance therapy for refractory or recurrent disease.

Recent Findings:

In the last several years, several observational studies have reported the clinical benefit of mepolizumab and benralizumab in refractory EM.

Summary:

EM is a complex and heterogenous cause of inflammatory heart disease with a wide range of etiologies and presentations. Treatment of this disease has not been standardized as there are no large scale trials quantifying benefit of any specific therapy regimen. Targeted biologics show promise in observational studies; therefore, prospective studies are needed to quantify this benefit in EM.

01 Dec 2025·CURRENT ALLERGY AND ASTHMA REPORTS

Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy

Review

Author: Reitsma, Sietze ; Fokkens, Wytske Johanna ; Otten, Josje Janna

PURPOSE OF REVIEW:

Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.

RECENT FINDINGS:

Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes. Patients with CRSwNP appear capable of reliably evaluating their olfactory function. Standard treatment such as intranasal corticosteroids and surgery have limited capability of restoring the sense of smell. Oral corticosteroids have a far greater potency, albeit short-lived and at the cost of adverse events and side effects. Recent studies on registered biological agents- specifically dupilumab, mepolizumab, and omalizumab- indicate their effectiveness in restoring olfactory function in severe CRSwNP. According to meta-analyses and indirect comparisons, dupilumab shows superiority; however, direct comparative studies are necessary.

137

News (Medical) associated with Mepolizumab

13 Aug 2025

·www.einpresswire.com

Family Allergy & Asthma Research Institute Contributes to Groundbreaking Global Study on Severe Asthma Treatment

FAA Research Institute contributes to global study proving mepolizumab's effectiveness in reducing severe asthma exacerbations Our team’s commitment to advancing asthma care through research is unwavering, showcasing how collaboration and innovation improve patient outcomes.” — Dr. Stephen Pollard LOUISVILLE, KY, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Family Allergy & Asthma (FAA) is proud to announce that Dr. Stephen Pollard, Principal Investigator at the FAA Research Institute, has been published as a co-author in the prestigious Annals of Allergy, Asthma & Immunology. The study, titled “ Mepolizumab Real-World Effectiveness in Severe Asthma with an Eosinophilic Phenotype and Overlapping Severe Allergic Asthma,” represents a significant advancement in the understanding and treatment of severe asthma. This large-scale, real-world study highlights the effectiveness of mepolizumab, a biologic therapy targeting eosinophilic inflammation, in reducing asthma exacerbations in patients with overlapping allergic and eosinophilic phenotypes. The findings provide critical insights for clinicians managing complex asthma cases, where multiple biologic treatment options may be considered. A Team Effort in Research Excellence The success of this study is a testament to the dedication and expertise of the FAA Research Institute team. Research coordinators Becky Whitehead and Amber Noe played a pivotal role in patient recruitment, retention, and data management, ensuring the study’s success. While not listed as authors, their behind-the-scenes contributions were instrumental and reflect the high standards of FAA’s clinical research staff. “Our team’s commitment to advancing asthma care through research is unwavering,” said Dr. Stephen Pollard. “This study is a prime example of how collaboration and innovation can lead to meaningful improvements in patient outcomes.” Join the FAA Research Institute’s Mission Since 1991, the FAA Research Institute has been at the forefront of clinical research, contributing to the development of groundbreaking treatments like Zyrtec, Allegra, Claritin, Flonase, and Nasonex. Located at the Goss Avenue location in Louisville, KY, the institute boasts state-of-the-art technology and a computerized database of over 15,000 patients. The institute collaborates with leading national pharmaceutical and clinical research organizations, ensuring that all studies are closely monitored by the FDA and Institutional Review Boards to prioritize participant safety and rights. Why Participate in Clinical Research? Participants in FAA’s clinical trials benefit from: Personalized care with close monitoring of health conditions. Access to study-related office visits, physician exams, and medications. Reimbursement for time and travel. The opportunity to contribute to advancements in treatments for asthma, allergies, and other conditions. “Our research is fueled by a shared goal to enhance lives through evidence-based findings and innovations,” said Becky Whitehead, Director of Clinical Research. “By joining our studies, participants not only gain access to cutting-edge treatments but also play a vital role in shaping the future of care.” Current Research Opportunities The FAA Research Institute is currently recruiting participants for studies on asthma, food allergies, COPD, dermatitis, and more. To learn more about ongoing trials or to participate, contact the FAA Research Institute at 502.368.0732 or visit familyallergy.com. Advancing Asthma Care Through Cutting-Edge Research Family Allergy & Asthma’s participation in this peer-reviewed publication underscores its dedication to leading-edge research and evidence-based treatment. By contributing to the evolving landscape of biologic therapies for severe asthma, FAA continues to support clinicians and patients in making informed treatment decisions. About Family Allergy & Asthma Research Institute Family Allergy & Asthma is a leading provider of allergy and asthma care, offering comprehensive services to patients across Louisville, KY. With a strong focus on clinical research, FAA is committed to improving the lives of individuals with asthma and allergies through innovative treatments and personalized care. For more information about this study or Family Allergy & Asthma’s research initiatives, please contact Research Department Director Becky White at bwhite@familyallergy.com Becky Whitehead Family Allergy & Asthma +1 502-368-0732 bwhite@familyallergy.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Study

30 Jul 2025

·www.fiercepharma.com

Despite Blenrep uncertainty, GSK sticks to its £40B sales projection for 2031

GSK is sticking to its 2031 sales projection of 40 billion pounds ($53 billion), regardless of whether it regains a key FDA approval of blood cancer treatment Blenrep. With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ($53 billion) in 2031, regardless of whether it regains U.S. approval of key blood cancer drug Blenrep.Earlier this month, an FDA advisory committee voted down the previously approved treatment, saying its risk exceeded its benefit, with the recommendation that it should remain sidelined. The FDA is scheduled to deliver an approval verdict for Blenrep on October 23.“There is absolutely no change to our expectations,” Emma Walmsley, GSK’s CEO, said in a quarterly conference call. “No update at all, except for reiterating our confidence in terms of our outlooks.”For the most part, GSK stiff-armed questions about Blenrep and U.S. tariffs on Wednesday, but the British company was more than happy to discuss its growing portfolio of treatments for chronic obstructive pulmonary disease (COPD).With respect to its launch of IL-5 inhibitor Nucala to treat COPD, GSK said that the drug is off to a promising start in the indication compared to its rival, Sanofi and Regeneron’s Dupixent. The drugs are the first two biologics cleared for the disease, both as add-on maintenance treatments for patients whose COPD is inadequately controlled.“If I look at initial signs, we’re already ahead of where Dupixent was at this point of its launch, with new patient starts,” Luke Miels, GSK’s chief commercial officer, said on the call. Dupixent got a head start in the indication, winning FDA approval last September, while Nucala captured its U.S. nod two months ago.GSK touted Nucala’s 35% reduction in hospitalization and emergency room visits, which was demonstrated in a phase 3 trial, as helping spur the strong initial uptake.“If you look at marketing research—again, early days—67% of pulmonologists said they’re likely to prescribe Nucala in COPD and prefer it versus only 30% for Dupixent,” Miels said. “Pulmonologists historically have not been as aggressive as maybe the evidence would support in terms of biologic penetration.” Treating COPD patients is a major priority for GSK, as indicated by its deal announced Monday with China’s Hengrui Pharma. GSK is paying $500 million up front and has promised $12 billion in potential milestone payments to develop 12 early-stage treatments. The only program named by the companies was a COPD candidate.As for the second quarter, GSK fared well overall, with sales coming in at 7.99 billion pounds ($10.6 billion). That marked an increase of 1% year over year and 6% sequentially. The company credited its specialty medicines for the growth, which were up 15%.GSK did not adjust its 2025 revenue guidance but did say that it expects to be at the top end of its expected 3% to 5% sales increase window for the full year.

Phase 3Accelerated ApprovalDrug Approval

28 Jul 2025

·www.fiercepharma.com

Another FDA mini-pause for Bayer’s menopause candidate?

Drug approval delays have become more common since the FDA lost 19% of its workforce in April due to federally mandated budget cuts. After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet drug approval deadlines. The latest example is its failure to rule on Bayer’s menopause treatment, elinzanetant.On Friday, the German company said in a release that the FDA needed additional time to review its new drug application for elinzanetant, extending the Prescription Drug User Fee Act (PDUFA) review period by up to 90 days.The FDA was expected to make its decision by Saturday on the application, which was filed in August 2024. The new PDUFA date is Oct. 26.Bayer added that the FDA did not “raise any concern regarding the general approvability” of elinzanetant. Earlier this month, regulators in the U.K. endorsed the treatment, which is known commercially as Lynkuet. Canada followed suit last week with a thumbs-up, while a review is ongoing by the European Union.“We are confident in the potential of elinzanetant to provide meaningful clinical benefit to women pending regulatory approval,” Yesmean Wahdan, M.D., Bayer’s head of medical affairs in North America, said in a statement. “We continue to work with the FDA to make this treatment available.”Analysts at Barclays wrote that the delay was a “small negative” for Bayer, which has tabbed peak sales for the treatment at 1 billion euros ($1.2 billion). The company will likely add more details during its second-quarter earnings presentation on Aug. 6.Over the past four months, the FDA has delayed its review of several drugs, but most decisions have still arrived relatively quickly. In May, the agency approved GSK’s Nucala for COPD less than two weeks after its original PDUFA date.In July, the FDA signed off on KalVista’s rare disease drug Ekertly three weeks after its original PDUFA date. And in April and May, it took an extra six weeks to convert Novavax’s COVID-19 vaccine from accelerated to full approval. In May, the FDA took an extra month to reject a rare-disease drug from Stealth BioTherapeutics, though that application has been through a series of regulatory challenges since the Massachusetts company first presented data in 2019.Last week, the FDA also delayed a decision on GSK’s multiple myeloma drug Blenrep by 90 days, which was voted down as an agent in two separate combinations by an FDA advisory committee earlier this month.As for Bayer, it is hoping to join Astellas as the second company with a hormone-free treatment for patients with moderate to severe hot flashes that accompany menopause. While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for the indication, Lynkuet is the first dual-action neurokinin in the indication, targeting the NK-3 and NK-1 receptors. Astellas reported 2024 fiscal year sales of Veozah at 33.8 billion yen ($230 million), which came up short of its expectations. Astellas has projected fiscal 2025 sales at 50 billion yen ($340 million). The company's peak sales projection for the treatment, which carries a black box warning for potential liver damage, is $3.6 billion.Despite being from the same treatment class, Lynkuet has shown scant evidence of the side effects in three phase 3 trials.

Drug ApprovalPhase 3VaccineClinical ResultAccelerated Approval

100 Deals associated with Mepolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04923	Mepolizumab	R03DX09	DB06612

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	United States	GSK Plc	22 May 2025
Asthma	Japan	GlaxoSmithKline KK	25 Mar 2020
Chronic rhinosinusitis with nasal polyps	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Severe asthma	United States	GlaxoSmithKline LLC	04 Nov 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Eosinophilia	NDA/BLA	China	GlaxoSmithKline (China) Investment Co., Ltd.	14 Mar 2023
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	China	GSK Plc	22 Apr 2021
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	Japan	GSK Plc	22 Apr 2021
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	Russia	GSK Plc	22 Apr 2021
Eosinophilia	Phase 3	United Kingdom	GSK Plc	07 Sep 2020
Nasal Polyps	Phase 3	United States	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Argentina	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Australia	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Canada	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Germany	GSK Plc	25 May 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04133909 (MATINEE, CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	806	Mepolizumab (Mepolizumab 100 mg)	udvrokneyv(adhtncuhxg) = kcjyzltyay ckecqpotuq (entqeoqfft, rvfjzvajgg - kodygoyplv) View more	-	15 Aug 2025
				Placebo (Placebo)	udvrokneyv(adhtncuhxg) = uimckxnich ckecqpotuq (entqeoqfft, kjuwgfzbfh - egdvkuvlkq) View more
NEST (ATS2025)	Not Applicable	Severe asthma eosinophilic phenotype	306	Mepolizumab 100 mg	qptghzxmts(qtegzwihff) = xudzvlhwve ptnpvvzczf (uexeuwtcyh ) View more	Positive	16 May 2025
				Maintenance OCS (mOCS)	qptghzxmts(qtegzwihff) = tewoqghzaf ptnpvvzczf (uexeuwtcyh ) View more
NCT04765722 (MUCOSA, ATS2025)	Phase 4	Refractory chronic cough sputum eosinophilia	30	Mepolizumab 100 mg	yqbhugvfns(yjmwceiwyv): % = 18.6 (95% CI, -23 to 82), P-Value = 0.44	Negative	16 May 2025
				Placebo
ATS2025	Not Applicable	Severe asthma	308	Mepolizumab	qhepnlvxlp(hhchbaltyf) = acuezdcpaq kbsruijeac (rrurwjwuwq ) View more	Positive	16 May 2025
JPRN-UMIN000045021 (J-Real-Mepo Study, ATS2025)	Not Applicable	Galectin-10 (Gal10) \| TARC \| peripheral blood eosinophil counts	78	Mepolizumab	tekjippzar(ucxijmwyaw) = ppbdgtrftq djcojwrhlw (oeyhsxcsel ) View more	Positive	16 May 2025
NEST (ATS2025)	Not Applicable	Severe asthma eosinophilic phenotype	174	Mepolizumab	wknmccrhwo(wvrxhviirl): incident rate ratio = 0.26 (95% CI, 0.18 - 0.36)	Positive	16 May 2025
				Previous Biologic Treatments
NCT03562195 (Pubmed \| Allergy Asthma Immunol Res)	Phase 3	Severe asthma	300	Mepolizumab	tirvrirktx(tnckzdbsoa) = xdovxqsdma dncnrxcvhy (lmhatykvxd ) View more	Positive	01 Jan 2025
				Placebo	tirvrirktx(tnckzdbsoa) = lljyxqfexz dncnrxcvhy (lmhatykvxd ) View more
NCT04276233 (PRISM, CTgov)	Phase 4	Asthma \| Eosinophilic Asthma	100	Mepolizumab	ijsfsnvavh = cjlqduqoix npzpvxjech (ouhkisnrdg, tiwodgtsxg - rmltisavmt) View more	-	10 Dec 2024
NCT04607005 (MERIT, CTgov)	Phase 3	Asthma, Nasal Polyps, and Aspirin Intolerance \| Nasal Polyps \| Chronic rhinosinusitis with nasal polyps	169	Mepolizumab (Mepolizumab)	ydsihrcour(iwqsjnegjx) = jdbwwwzyzu xkuuneogxm (wuaxdefrqr, 0.164) View more	-	25 Nov 2024
				placebo (Placebo)	ydsihrcour(iwqsjnegjx) = bktnzjxtsr xkuuneogxm (wuaxdefrqr, 0.164) View more
NCT00244686 (Pubmed) Manual	Phase 3	Severe asthma	514	Mepolizumab 100 mg SC (Adults/adolescents (≥12 years of age))	krtvukkcwi(vajfjidkii) = ilhdufrwwl uaoyzliwnt (vzcjtapoyh )	Positive	28 Oct 2024
				Mepolizumab 40 mg or 100 mg SC (bodyweight <40 or ≥40 kg, respectively) (Pediatric patients (6-11 years of age))	-

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data